FAS managed to save 5 billion RUB in medicinal drug procurement

27-12-2016 | 13:34

“Pharmaceutical companies reduced prices for 88 positions of vital medicines; the saving of budgetary funds in medicinal drug procurement will be minimum 5 billion RUB per year”, said Head of FAS Department for Control over Social Sphere and Trade, Timophey Nizhegorodtsev at a press-conference on 26 December at “Russia Today” International information Agency.

Prices went down upon the findings of an investigation carried out by the Federal Antimonopoly Service (FAS Russia) following the instructions from the President of the Russian Federation. At the first stage of the study the antimonopoly body compared the costs of vital drugs procured by the state under the “7 Nosologies” programme.

Overall FAS revealed 66 drugs, prices for which were overrated in Russia. Along with the companies, caught fixing excessive prices, Russian pharmaceutical manufacturers also voluntarily decreased prices, therefore, demonstrating social responsibility.

Foreign companies reduced prices by 21-88%; the reduction reached on average 50% (in Rubles the most significant reduction was 240,000 RUB for “Revlimid” produced by “Selgen” to treat oncological diseases).

FAS is continuing an international comparative study of prices for other drug groups. In January 2017 the antimonopoly body will present the results of analyzing prices for treating HIV, tuberculosis and hepatitis, for which lower prices in the reference countries were found.



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD UN Conference Resolution of the Conference Russian contributions EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide